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ABSTRACT
Aims/Introduction: Epigenetics participate in the pathogenesis of metabolic memory,
a situation in which hyperglycemia exerts prolonged deleterious effects even after its nor-
malization. We tested the hypothesis that genetic variants in an epigenetic gene could
predispose to diabetes complications.
Material and Methods: We assessed the frequency of five single-nucleotide polymor-
phisms in the gene encoding deoxyribonucleic acid methytransferase 1 (DNMT1;
rs8112895, rs7254567, rs11085721, rs17291414 and rs10854076), and their associations with
diabetic kidney disease, retinopathy, distal polyneuropathy and autonomic cardiovascular
neuropathy in 359 individuals with long-term type 1 diabetes.
Results: None of the single-nucleotide polymorphisms studied was significantly associ-
ated with the presence of chronic complications in the overall population. However, after
sex stratification, the minor allele C of rs11085721 conferred risk for cardiovascular neu-
ropathy in women after adjustment for confounding variables (odds ratio 2.32; 95% confi-
dence interval 1.26–4.33; P = 0.006).
Conclusions: The fact that heterozygous mutations in DNMT1 are associated with
hereditary sensory autonomic neuropathy provides plausibility to the present finding. If
confirmed in independent samples, it suggests that genetic variants in epigenetic genes
might predispose to more or fewer epigenetic changes in the face of similar metabolic
derangements triggered by hyperglycemia, constituting the “genetics of epigenetics” for
microvascular diabetes complications.
INTRODUCTION
Epigenetic changes participate in the pathogenesis of diabetes
complications; periods of hyperglycemia cause permanent
abnormalities, such as aberrant gene expression, in target tissues
of complications. This phenomenon is called metabolic mem-
ory and explains why hyperglycemia exerts persistent deleteri-
ous effects even after its normalization1.
Deoxyribonucleic acid methyltransferases (DNMTs) add a
methyl group at cytosine residues located in CpG islands from
the promoter regions of genes, resulting in gene silencing2. Our
literature search did not reveal studies evaluating the associa-
tion between diabetes complications and DNMT polymor-
phisms.
To investigate the participation of “genetics of epigenetics”
in diabetes complications, we evaluated the association between
DNMT1 single-nucleotide polymorphisms (SNPs) and diabetic
kidney disease (DKD), retinopathy (DR), distal polyneuropathy
and cardiovascular autonomic neuropathy (CAN). The minor
allele of one of the evaluated SNPs (rs11085721) conferred risk
for CAN in women, suggesting that genetic variants in
epigenetic genes participate in the susceptibility to this
complication.Received 6 June 2018; revised 29 October 2018; accepted 9 December 2018
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A total of 359 individuals with type 1 diabetes were recruited
from two university hospitals. Type 1 diabetes was diagnosed
in the presence of hyperglycemia, undetectable C-peptide or
ketoacidosis and positive autoantibodies (glutamic acid decar-
boxylase, islet cell antibodies or tyrosine phosphatase-like insuli-
noma antigen 2). All participants were under permanent
insulin treatment initiated at diagnosis or within 6 months of
diagnosis. Inclusion criteria were type 1 diabetes dura-
tion ≥10 years and glycated hemoglobin >8% in any period of
life. Exclusion criteria were hypocortisolism and use of medica-
tions interfering with heart rate. The study was carried out in
compliance with the Declaration of Helsinki, in accordance
with institutional ethics committees.
After signing informed consent, participants were evaluated
for clinical and biochemical characteristics, and for the status
of DKD, DR, polyneuropathy and CAN, as previously
described3. Briefly, DKD was diagnosed in the presence of
macroalbuminuria (albumin : creatinine ratio >300 mg/g)
and/or reduced estimated glomerular filtration rate (<60 mL/
min 1.73/m2, as calculated by Chronic Kidney Disease
Epidemiology Collaboration4). Standardized seven-field retinal
color photographs with the use of TRC-NW8 Non-Mydriatic
Retinal Camera (Topcon, Oakland, NJ, USA) was used for
the diagnosis of DR; the images were evaluated by a single
ophthalmologist trained in DR following the international
classification of DR5. Polyneuropathy was diagnosed by the
sum of the Neuropathy Symptoms Score and Modified Neu-
ropathy Disability Score6. CAN was diagnosed based on
Ewing tests, spectral analysis of the heart rate variability and
systolic blood pressure after 3 min standing. Seven variables
were evaluated: (i) spectral power in the low frequency band;
(ii) spectral power in the high-frequency band; (iii) spectral
power in the very low-frequency band; (iv) maximum/mini-
mum 30:15 ratio; (v) expiration : inspiration ratio; (vi) Val-
salva ratio; and (vii) postural change in systolic blood
pressure. Diagnosis of CAN was made in the presence of
three or more abnormal tests7.
Genotype Analysis
Deoxyribonucleic acid extraction from peripheral blood leuko-
cytes was carried out by a salting-out procedure8. To cover
most of the genetic variability across the extended region of
Table 1 | Characteristics of individuals with type 1 diabetes (overall and sorted according to the presence or absence of cardiovascular autonomic
neuropathy)
Overall Without CAN With CAN P-value
Clinical and biochemical characteristics
n 359 238 121
Age (years) 36 (29–45) 37 (29–46) 35 (30–44) 0.39
Sex, female (%) 59.6 59.2 60.3 0.35
BMI (kg/m2) 24.1 (21.7–26.8) 24 (22–27) 24 (21–28) 0.78
Arterial hypertension (%) 50.1 42 67 <0.0001
Dyslipidemia (%) 46 43 52 0.19
Total cholesterol (mg/dL) 173 (148–195) 171 (149–192) 177 (145–215) 0.17
HDL cholesterol (mg/dL) 58 (46–71) 59 (47–73) 58 (46–67) 0.37
LDL cholesterol (mg/dL) 94 (80–110) 94 (80–107) 95 (77–124) 0.45
Triglycerides (mg/dL) 78 (58–107) 76 (57–98) 90 (63–130) 0.0004
eGFR (mL/min.1.73 m2) 97 (64–112) 100 (78–115) 81 (16–106) <0.0001
Diabetes status
Diabetes duration (years) 23 (18–30) 23 (18–30) 24 (18–30) 0.99
Age at diagnosis (years) 12 (7–18) 12 (7–19) 11 (6–18) 0.25
HbA1c (%) 8.2 (7.4–9.4) 8.1 (7.3–9.0) 8.5 (7.5–10) 0.004
Fructosamine (lmol/L) 369 (322–430) 367 (322–415) 384 (319–481) 0.15
Microvascular complications
Diabetic kidney disease (%) 29.8 20 52.3 <0.0001
Retinopathy (any degree) (%) 69 64.7 79.3 0.01
Distal polyneuropathy (%) 34.5 26.7 57 <0.0001
Use of medicines
ACEI (%) 35 33 42 0.01
Statin (%) 45 41 52 0.02
Results expressed as median and interquartile range, and percentage of cases (categorical variables). Glycated hemoglobin (HbA1c) is expressed as
the percentage of total hemoglobin. P ≤ 0.05 was considered significant. ACEI, angiotensin-converting enzyme inhibitors; BMI, body mass index;
eGFR, estimated glomerular filtration rate computed with the Chronic Kidney Disease Epidemiology Collaboration equation; CAN, cardiac autonomic
neuropathy; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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DNMT1 (including regions spanning 15 kb upstream and
downstream of the gene), five tag SNPs were chosen based on
the Haploview program (http://www.broadinstitute.org/scientif
iccommunity/science/programs/medical-and-populationgenetics/
haploview/haploview) and on HapMap (http://hapmap.ncbi.
nlm.nih.gov), using a pair-wise approach, a r2 ≥ 0.9 and a
minor allele frequency of >0.05: rs8112895, rs7254567,
rs11085721, rs17291414 and rs10854076. Based on Haploreg
(https://pubs.broadinstitute.org/mammals/haploreg/haploreg.
php), rs8112895 and rs10854076 are intronic SNPs, whereas
the remaining are non-intronic SNPs: rs7254567 and
rs11085721 are located 12 kb 50 of DNMT1, and rs17291414 is
located 11 kb 50 of DNMT1.
SNPs were genotyped by real-time polymerase chain reaction
(StepOne Plus; Applied Biosystems, Foster City, CA, USA),
using predesigned Human TaqMan Genotyping Assays 40X:
C__29287779_10 (rs8112895), C__34042774_10 (rs17291414),
C__31764973_10 (rs11085721), C__26941571_10 (rs7254567)
and C___1142308_10 (rs10854076; Thermo Fisher Scientific,
Waltham, MA, USA). The genotyping success rate was ~99%
for all SNPs, and SNP/sample call rates were >99%.The Hardy–
Weinberg equilibrium was tested for all SNPs, and the only
one with a P-value <0.05 was rs8112895, which was not con-
sidered in the association analysis.
Statistical Analysis
Differences between groups were assessed by Pearson’s
v2-test and Wilcoxon/Mann–Whitney tests (nominal and
continuous variables, respectively). The associations of
the genotypes (co-dominant model) with complications
were assessed by logistic regression analyses to compute
odds ratios and 95% confidence intervals. Adjustments
for confounding variables were carried out by including
them as covariates in the regressive model. Interaction
between genotype and sex was evaluated by including a
“crossed” compound covariate (sex/genotype) in the
regression models. The stratification by sex was then car-
ried out by nesting the genotype variable within the sex
variable in the analysis model. This results in the com-
putation of statistical effects for men and women sepa-
rately. Correction for multiple comparisons due to
multiple SNP testing took into account the effective
number of independent tests (Meff) based on the degree
of linkage disequilibrium between SNPs, and P < 0.01
was considered significant9. The power to detect associa-
tions with CAN was 84% for rs11085721 in the female
population. Statistics were carried out with the JMP soft-
ware (SAS Institute, Cary, NC, USA).
RESULTS
The characteristics of the individuals with type 1 diabetes (over-
all and sorted according to status of CAN, the only complica-
tion associated with one of the evaluated SNPs) are shown in
Table 1. A total of 121 out of 359 participants (33.7%) had the
clinical form of CAN (≥3 altered tests). Individuals with CAN,
when compared with individuals without CAN, presented a
higher prevalence of hypertension, higher triglyceride and gly-
cated hemoglobin concentrations, and lower estimated glomeru-
lar filtration rate. DKD, DR, polyneuropathy, and use of
angiotensin-converting enzyme inhibitors and of statins were
more frequent in the group presenting CAN.
None of the studied SNPs was significantly associated with
the presence of the evaluated chronic complications in the
overall population (data shown for CAN in Table 2, data for
DKD, DR and distal polyneuropathy are available as Support-
ing Information in Tables S1, S2 and S3, respectively). SNP
rs11085721 showed a significant interaction with sex
(P = 0.005). After sex stratification, the minor allele C of this
SNP conferred risk for CAN in women with type 1 diabetes
after adjustment for glycated hemoglobin, triglycerides,
estimated glomerular filtration rate, the presence of hyperten-
sion and use of medicines (angiotensin-converting enzyme
inhibitors and statin; odds ratio 2.32, 95% confidence interval
1.26–4.33; P = 0.006; Table 3).
Table 2 | Genotype frequencies of four single-nucleotide
polymorphisms in DNMT1 according to the status of cardiovascular
autonomic neuropathy in the overall individuals with type 1 diabetes























Odds ratio (OR) for the minor allele determined in logistic regression in
a co-dominant model analysis adjusted for glycated hemoglobin,
triglyceride concentrations, estimated glomerular filtration rate, the pres-
ence of hypertension and use of medicines (angiotensin-converting
enzyme inhibitors and statins). P ≤ 0.01 is considered significant. CAN,
cardiovascular autonomic neuropathy; CI, confidence interval; MAF,
minor allele frequency; SNP, single-nucleotide polymorphism.
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DISCUSSION
This is one of the rare studies showing the association of a SNP
in a gene involved in epigenetic modification with diabetes com-
plication. The presence of the minor allele C of rs11085721 in
DNMT1 conferred risk for CAN in women with type 1 diabetes.
CAN is one of the least recognized diabetes complications,
even though it can have serious consequences; it affects the
autonomic nerves that innervate heart and blood vessels, caus-
ing sympathovagal imbalance, heart rate deregulation and car-
diac impairment. CAN is also an independent predictor factor
for cardiovascular mortality and progression of DKD10.
As for other diabetes complications, poor glycemic control is
the most important risk factor for CAN development and pro-
gression. After 14 years of follow up of the Diabetes Control
and Complications Trial cohort in the Epidemiology of Dia-
betes Interventions and Complications study, a higher incidence
of CAN was observed in the group exposed to suboptimal
metabolic control (conventional therapy during the Diabetes
Control and Complications Trial), showing the persistent dele-
terious effects of hyperglycemia. This finding supports the
impact of metabolic memory on CAN development, which was
not as evident for distal polyneuropathy11,12.
The fact that heterozygous mutations in DNMT1 are associ-
ated with hereditary sensory autonomic neuropathy13 provides
plausibility to our finding. However, it is interesting that
rs11085721 conferred susceptibility for CAN, but not for
peripheral neuropathy. This SNP has previously been associated
with increased susceptibility to acute lymphoblastic leukemia14
and to an increased risk of attempted suicide only in women15,
but there are no functional studies reported for it. Thus, it is
not possible to know whether rs11085721 confers susceptibility
to CAN or if it is in linkage disequilibrium with the susceptibil-
ity SNP.
We do not have an explanation for the sex-specific associa-
tion, but sexual dimorphism is reported in several pathological
conditions and might result from sex hormone-induced differ-
ences in the epigenetic status of key genes16. It is worth men-
tioning that animal studies have shown greater DNMT1
activity in males than in females17.
Despite the ethnic admixture that characterizes the Brazilian
population, the minor allele frequency observed in this series
(0.1765) is similar to that reported in the National Center for
Biotechnology Information Single Nucleotide Polymorphism
Database for Caucasian populations (0.144–0.166), which
decreases the probability of the observed result being a false posi-
tive association. However, the present finding must be interpreted
in the context of limitations of cross-sectional studies. If con-
firmed in larger and independent samples, it suggests that genetic
variants in epigenetic genes might predispose to more or fewer
epigenetic changes in the face of similar metabolic derangements
triggered by hyperglycemia, constituting the “genetics of epige-
netics” for microvascular diabetes complications.
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Table S1 | Genotype frequencies of four single-nucleotide polymorphisms in DNMT1 according to the status of diabetic kidney
disease in the overall individuals with type 1 diabetes.
Table S2 | Genotype frequencies of four single-nucleotide polymorphisms in DNMT1 according to the status of diabetic retinopa-
thy in the overall individuals with type 1 diabetes.
Table S3 | Genotype frequencies of four single-nucleotide polymorphisms in DNMT1 according to the status of diabetic distal
polyneuropathy in the overall individuals with type 1 diabetes.
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